{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:39:08Z","timestamp":1781915948314,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116596","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:14:31Z","timestamp":1772730871000},"page":"116596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lanoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Qu\u00e9reux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuelle","family":"Viguier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Dinulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Legoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve Marie","family":"Neidhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Trabelsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"C\u00e9l\u00e9rier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlee","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Maubec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Benedicte","family":"Duval- Modeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Hainaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Guegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Arnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Stoebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"LE Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Peuvrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertille","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Herrscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Granel-Brocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-lise","family":"Vataire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Tabellion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2026.116596_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","article-title":"Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging","volume":"78","author":"Que","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116596_bib2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-18-1122","article-title":"Keratinocyte carcinomas: current concepts and future research priorities","volume":"25","author":"Nagarajan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.116596_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/jid.2013.304","article-title":"Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence","volume":"134","author":"Eisemann","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116596_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/biomedicines9020171","article-title":"Cutaneous squamous cell carcinoma: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Fania","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejca.2026.116596_bib5","doi-asserted-by":"crossref","first-page":"324e31","DOI":"10.1111\/bjd.12988","article-title":"Increasing skin cancer incidence in young, affluent, urban populations: a challenge for prevention","volume":"171","author":"Deady","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116596_bib6","doi-asserted-by":"crossref","first-page":"298e306","DOI":"10.1001\/jamadermatol.2018.4219","article-title":"Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England","volume":"155","author":"Venables","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116596_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.17873","article-title":"Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013\u201315: a cohort study","volume":"181","author":"Venables","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116596_bib8","doi-asserted-by":"crossref","first-page":"472e80","DOI":"10.1002\/cam4.404","article-title":"Cutaneous squamous cell carcinoma in Norway 1963-2011: increasing incidence and stable mortality","volume":"4","author":"Robsahm","year":"2015","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.ejca.2026.116596_bib9","doi-asserted-by":"crossref","first-page":"adv00143","DOI":"10.2340\/00015555-3498","article-title":"Update of the management of cutaneous squamous-cell carcinoma","volume":"100","author":"Maubec","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2026.116596_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2023.01.017","article-title":"Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland","volume":"183","author":"Keim","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116596_bib11","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: diagnostics and prevention-update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2026.116596_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jso.23155","article-title":"The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors","volume":"106","author":"Brougham","year":"2012","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116596_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012","volume":"68","author":"Karia","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116596_bib14","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: part 2. Treatment-update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116596_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13325","article-title":"Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma","volume":"33","author":"Benzaquen","year":"2020","journal-title":"Dermatol Ther"},{"issue":"25","key":"10.1016\/j.ejca.2026.116596_bib16","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2026.116596_bib17","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1002\/cam4.3146","article-title":"Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy","volume":"9","author":"Cowey","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116596_bib18","unstructured":"Cemiplimab FDA approval. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma. Accessed on June 27, 2023."},{"key":"10.1016\/j.ejca.2026.116596_bib19","unstructured":"European Medicines Agency. Libtayo (cemiplimab). Available at: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/overview\/libtayo-epar-medicine-overview_en.pdf\u3009. Accessed on June 27, 2023."},{"issue":"4","key":"10.1016\/j.ejca.2026.116596_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2026.116596_bib21","doi-asserted-by":"crossref","first-page":"S918","DOI":"10.1016\/j.annonc.2022.07.940","article-title":"Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3","volume":"33","author":"Migden","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116596_bib22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116596_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/fon-2020-0823","article-title":"Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma","volume":"17","author":"Keeping","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2026.116596_bib24","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase ii trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116596_bib25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, non-randomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116596_bib26","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2026.116596_bib27","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.3390\/cancers13143547","article-title":"Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: real-life experience from the French CAREPI study group","volume":"13","author":"Hober","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ejca.2026.116596_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5694\/mja2.52199","article-title":"Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study","volume":"220","author":"McLean","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejca.2026.116596_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40487-023-00256-1","article-title":"A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario","volume":"12","author":"Di Lorenzo","year":"2024","journal-title":"Oncol Ther"},{"key":"10.1016\/j.ejca.2026.116596_bib30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116596_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2018.01.075","article-title":"Dermatologic Cooperative Oncology Group (DeCOG). Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG","volume":"96","author":"Hillen","year":"2018","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2026.116596_bib32","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.116596_bib33","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116596_bib34","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Libtayo 350 mg. Available at: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-20301_LIBTAYO_PIC_REEV_AvisDef_CT20301.pdf. Accessed on April 15, 2024."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600376X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600376X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:59:44Z","timestamp":1776095984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600376X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"alternative-id":["S095980492600376X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116596","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116596"}}